Difference between revisions of "Breast cancer"
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
=====References===== | =====References===== | ||
# Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/21376385 PubMed] | # Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext link to original article] '''(contains protocol)''' [http://www.ncbi.nlm.nih.gov/pubmed/21376385 PubMed] | ||
| + | |||
| + | ====Ixabepilone (Ixempra)==== | ||
| + | *[[Ixabepilone (Ixempra)]] 40 mg/m2 IV on day 1 | ||
| + | *[[Capecitabine (Xeloda)]] 2,000 mg/m2 orally on days 1 through 14 | ||
| + | |||
| + | ''21-day cycles''' | ||
| + | |||
| + | =====References===== | ||
| + | #Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63. | ||
| + | [http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20530276/?tool=pubmed]'''(contains protocol)''' | ||
| + | [http://www.ncbi.nlm.nih.gov/pubmed/20530276 PubMed] | ||
| + | Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. | ||
| + | [http://www.jco.org/cgi/pmidlookup?view=long&pmid=17968020]'''(contains protocol)''' | ||
| + | [http://www.ncbi.nlm.nih.gov/pubmed/17968020 PubMed] | ||
Revision as of 08:28, 18 February 2012
Adjuvant Therapy
Metastatic Disease
Single agents
Eribulin (Halaven)
- Eribulin (Halaven) 1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8
21-day cycles
References
- Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. link to original article (contains protocol) PubMed
Ixabepilone (Ixempra)
- Ixabepilone (Ixempra) 40 mg/m2 IV on day 1
- Capecitabine (Xeloda) 2,000 mg/m2 orally on days 1 through 14
21-day cycles'
References
- Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63.
[1](contains protocol) PubMed Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. [2](contains protocol) PubMed